PPA Technologies

PPA Technologies is a biotechnology company specializing in the optimization of protein-protein interactions (PPIs) to develop next-generation therapeutics. Utilizing a proprietary platform developed at the Weizmann Institute of Science, the company focuses on engineering proteins with enhanced affinity and specificity. Their technology allows for the rapid screening and design of protein-based drugs, including antibodies and cytokines, by measuring binding kinetics in real-time. PPA Technologies aims to address unmet medical needs in oncology and immunology by improving the efficacy and safety profiles of biologic treatments. The company's approach streamlines the discovery process for high-potency therapeutic candidates by leveraging advanced computational and experimental methods. By focusing on the fundamental mechanics of protein binding, they create biologics with superior binding properties and reduced off-target effects.